DSGN - Design Therapeutics, Inc.

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1).

Jun 30, 2026 04:00 AM • globenewswire.com

Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.

Jun 24, 2026 02:07 PM • seekingalpha.com

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m.

May 28, 2026 04:00 AM • globenewswire.com

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.

May 18, 2026 10:26 AM • benzinga.com

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

May 18, 2026 07:00 AM • seekingalpha.com

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing

May 18, 2026 03:00 AM • globenewswire.com

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026.

May 17, 2026 12:00 PM • globenewswire.com

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.

May 17, 2026 12:00 PM • globenewswire.com

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

May 11, 2026 09:01 AM • zacks.com

Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript

Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript

Apr 29, 2026 11:11 PM • seekingalpha.com

Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution CARLSBAD, Calif.

Apr 28, 2026 12:01 PM • globenewswire.com

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026

Mar 09, 2026 12:01 PM • globenewswire.com

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong

Feb 19, 2026 08:33 PM • defenseworld.net

Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m.

Feb 18, 2026 03:00 AM • globenewswire.com

Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $10.13, but opened at $10.48. Design Therapeutics shares last traded at $10.10, with a volume of 9,741 shares changing hands. Analyst Ratings Changes DSGN has been the topic of several analyst

Jan 31, 2026 09:34 PM • defenseworld.net

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00

Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company.

Jan 25, 2026 08:00 PM • defenseworld.net

Design Therapeutics price target raised to $21 from $18 at Oppenheimer

$21.00 (was $13.30)

Oppenheimer

May 04, 2026 07:48 AM • TheFly

Design Therapeutics price target raised to $20 from $12 at Piper Sandler

$20.00 (was $15.24)

Piper Sandler

Apr 29, 2026 08:52 AM • TheFly

Design Therapeutics initiated with an Outperform at Oppenheimer

$18.00 (was $8.82)

Oppenheimer

Jan 07, 2026 06:32 AM • TheFly

Design Therapeutics initiated with a Buy at Craig-Hallum

$15.00 (was $8.94)

Adam Vogel · Craig-Hallum

Dec 03, 2025 07:38 AM • TheFly

Design Therapeutics upgraded to Outperform from Market Perform at Leerink

$14.00 (was $8.94)

Joseph Schwartz · Leerink Partners

Dec 03, 2025 06:11 AM • TheFly

Piper Sandler Upgrades Design Therapeutics Inc (DSGN) to Overweight

$12.00 (was $3.65)

Yasmeen Rahimi · Piper Sandler

May 06, 2024 11:04 PM • StreetInsider

Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments

$7.00 (was $2.17)

Leonid Timashev · RBC Capital

Aug 15, 2023 11:32 AM • Benzinga

Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler

$42.00 (was $12.69)

Yasmeen Rahimi · Piper Sandler

Dec 07, 2022 02:14 PM • TheFly

RBC Capital Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $30

$30.00 (was $11.94)

RBC Capital

May 02, 2022 02:21 AM • Benzinga

Design Therapeutics Stock (DSGN): $10 Price Target From Goldman Sachs

$10.00 (was $13.98)

Madhu Kumar · Goldman Sachs

Jan 18, 2022 07:00 PM • Pulse 2.0